“MaxCyte reported preliminary revenue above our updated total revenue guidance provided in December. The operating environment in the Cell Therapy industry was challenging in 2023; however, we remain confident in the opportunity that exists for MaxCyte in the years ahead,” said Maher Masoud, president and CEO of MaxCyte. “In 2023, we supported our partner, Vertex Pharmaceuticals Inc., in the approval of CASGEVY(TM), the first non-viral cell therapy product approved by the FDA. This milestone ushers in a new era of engineered cell therapies to treat diseases and validates the value of our platform. We are committed to supporting our partners in their commercial journeys and the profound impact they will make in patients’ lives.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MXCT:
- MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
- MaxCyte, Lion TCR announces the signing of a strategic platform license
- MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR’s TCR-T Cell Pipeline
- MaxCyte appoints Maher Masoud as CEO
- MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
